Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
相关临床试验
13
0 进行中
药物批准
6
批准总数
监管机构
1
监管机构数
成立时间
2002
Approved For Marketing
1
7.7%
已完成
8
61.5%
招募中
1
7.7%
终止
3
23.1%
- Catalyst Pharmaceuticals reported positive Phase I results showing vamorolone (Agamree) delivers anti-inflammatory activity without significant immunosuppression at clinical doses. - Part A demonstrated comparable cortisol suppression between vamorolone and deflazacort, supporting switching without dosing adjustments. - Part B found clinically relevant immunosuppression only at supratherapeutic doses (40 mg/kg/day), well above approved dosing levels. - Findings support potential label expansion into additional chronic inflammatory rare diseases beyond Duchenne muscular dystrophy.
- Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $4.1 billion ($31.50 per share), representing a 28% premium to the 30-day volume-weighted average trading price. - The transaction marks Angelini Pharma's strategic entry into the US market and strengthens its focus on rare neurological diseases through Catalyst's portfolio of FDA-approved treatments. - Catalyst's key products include FIRDAPSE for Lambert-Eaton myasthenic syndrome, AGAMREE for Duchenne muscular dystrophy, and FYCOMPA for epilepsy. - The deal is expected to close in the third quarter of 2026 and will be financed with support from Blackstone funds and BNP Paribas.
- Catalyst Pharmaceuticals and SERB S.A. have settled patent litigation with Hetero Labs Ltd., preventing generic competition for FIRDAPSE until January 2035. - The settlement resolves all pending FIRDAPSE patent litigation, following previous agreements with Lupin Pharmaceuticals, Teva Pharmaceuticals, and Inventia Healthcare Limited. - FIRDAPSE, approved for Lambert-Eaton Myasthenic Syndrome, continues to drive Catalyst's record financial performance with Q2 2025 revenues reaching $146.6 million, up 19.4% year-over-year. - Analysts maintain unanimous Strong Buy ratings with an average price target of $34, representing over 60% upside potential from current trading levels around $21.
- Santhera Pharmaceuticals received Swissmedic approval for AGAMREE (vamorolone) to treat Duchenne muscular dystrophy in patients four years and older, marking the company's seventh global marketing approval. - Nxera Pharma secured exclusive licensing rights for vamorolone in Japan, South Korea, Australia, and New Zealand through a $40 million upfront deal with potential milestone payments up to $165 million. - The novel dissociative steroid demonstrated superior safety compared to traditional corticosteroids, with five-year data showing reduced vertebral fractures, lower cataract incidence, and maintained normal growth rates. - AGAMREE met its primary endpoint in the pivotal VISION-DMD study with significant improvement in Time to Stand velocity versus placebo (p=0.002) at 24 weeks.
- Sironax appointed Nasir Khan, DVM, Ph.D., as Senior Vice President of Preclinical Development and Gary Ingenito, MD, Ph.D., as Senior Vice President of Clinical Development to strengthen its leadership team. - Dr. Khan brings over 30 years of experience leading nonclinical safety advancement for more than 400 preclinical candidates and 63 drug approvals including Celebrex, Ibrance, and Comirnaty. - Dr. Ingenito contributes three decades of pharmaceutical development experience across neuromuscular and neurodegenerative diseases, having previously served as Chief Medical and Regulatory Officer at Catalyst Pharmaceuticals. - The appointments support Sironax's pipeline advancement, which includes three clinical-stage programs and four potentially first- or best-in-class assets targeting age-related degenerative diseases.
- Health Canada has approved AGAMREE (vamorolone) as the first treatment for Duchenne muscular dystrophy in patients aged 4 years and older, marking a historic milestone for Canadian DMD care. - The approval was granted under Priority Review and is based on the pivotal VISION-DMD study, where AGAMREE met its primary endpoint with significant improvement in Time to Stand velocity versus placebo (p=0.002). - Unlike traditional corticosteroids, AGAMREE demonstrates comparable efficacy while showing no restriction of growth and no negative effects on bone metabolism, potentially offering a better-tolerated treatment option. - The Canadian Neuromuscular Disease registry estimates more than 800 boys and young men are living with DMD in Canada, representing a significant unmet medical need now addressed by this approval.
- Santhera Pharmaceuticals secured approximately CHF 20 million in additional funding from existing investors Highbridge and R-Bridge to accelerate the global rollout of AGAMREE (vamorolone) for Duchenne muscular dystrophy treatment. - Strong demand for AGAMREE has exceeded expectations across the US, Europe, and China, with over 1,000 patients treated worldwide and US sales reaching USD 49.4 million in the first half of 2025. - The funding comprises USD 13 million from a royalty monetization with R-Bridge and CHF 10 million from Highbridge through a convertible bond extension, supporting inventory expansion and launch acceleration. - AGAMREE represents a novel dissociative anti-inflammatory drug that demonstrated efficacy in the pivotal VISION-DMD study while potentially avoiding growth restrictions and bone metabolism issues associated with traditional corticosteroids.
- Catalyst Pharmaceuticals and SERB S.A. reached a settlement agreement with Lupin that prevents generic competition for FIRDAPSE (amifampridine) until February 25, 2035. - The settlement resolves patent litigation stemming from Lupin's attempt to market a generic version of the rare disease treatment before patent expiration. - Catalyst has now settled similar patent disputes with Teva Pharmaceuticals and Inventia Life Science, with ongoing litigation against Hetero remaining. - The agreement ensures continued market exclusivity for FIRDAPSE, a treatment for patients with rare and difficult-to-treat diseases, extending commercial protection by over a decade.
- Multiple high-profile ANDA litigation settlements were resolved in the second and third quarters of 2025, involving major pharmaceutical companies and generic manufacturers across diverse therapeutic areas. - Settlement agreements typically resulted in patent validity acknowledgments and injunctions against generic manufacturers, with most claims dismissed without prejudice while allowing FDA approval processes to continue. - Notable settlements included complex multi-patent disputes for blockbuster drugs like Rinvoq, Jardiance, Xifaxan, and Biktarvy, demonstrating the ongoing importance of patent protection strategies in pharmaceutical innovation.
- The National Comprehensive Cancer Network has updated its small cell lung cancer guidelines to include specific recommendations for Lambert-Eaton Myasthenic Syndrome (LEMS) diagnosis and treatment. - The guidelines now recommend neurological evaluation with VGCC antibody testing and consideration of amifampridine therapy in consultation with neurologists for LEMS management. - LEMS occurs in approximately 3% of small cell lung cancer patients, with 90% of cases remaining undiagnosed according to Catalyst Pharmaceuticals data. - Amifampridine remains the only FDA-approved therapy specifically for LEMS treatment, demonstrating significant efficacy in phase 3 trials.
